We are live on
!
Find out more
RG
Redmile Group Portfolio holdings
AUM
$1.49B
Turnover
10.26%
1-Year Est. Return
208.7%
This Fund
S&P 500
This Quarter
Est. Return
-10.28%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$1.32B
AUM Growth
+$99.8M
(+8.2%)
Cap. Flow
+$327M
Cap. Flow
% of AUM
24.74%
Top 10 Holdings %
Top 10 Hldgs %
52.92%
Holding
77
New
22
Increased
20
Reduced
12
Closed
19
Avg Time Held
0.6
years
Top 10 Avg Time Held
0.5
years
Top 20 Avg Time Held
0.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MDVN
MEDIVATION, INC.
MDVN
|
+$86.8M |
| 2 |
RAD
Rite Aid Corporation
RAD
|
+$67.2M |
| 3 |
Penumbra
PEN
|
+$63.2M |
| 4 |
Sage Therapeutics
SAGE
|
+$52.5M |
| 5 |
Incyte
INCY
|
+$50.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bausch Health
BHC
|
+$85.4M |
| 2 |
AGN
Allergan plc
AGN
|
+$41.5M |
| 3 |
KYTH
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
|
+$36.3M |
| 4 |
HCA Healthcare
HCA
|
+$35.4M |
| 5 |
AbbVie
ABBV
|
+$34.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 88.54% |
| 2 | Miscellaneous | 9.13% |
| 3 | Communication Services | 1.09% |
| 4 | Industrials | 1% |
| 5 | Technology | 0.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
VanEck Pharmaceutical ETF
PPH
$1.05B
| $409K | 0.03% |
6,500
| – | – |
2013 Q2
9 quarters
|
|
|
SRRA
52
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $377K | 0.03% |
+460
| New | +$519K |
2015 Q3
0 quarters
|
|
|
KDNY
53
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $311K | 0.02% |
3,211
-9,117
| -74% | -$1.09M |
2015 Q2
1 quarter
|
|
54
Jazz Pharmaceuticals
JAZZ
$13.6B
| $235K | 0.02% |
1,769
-149,097
| -99% | -$25.7M |
2015 Q1
2 quarters
|
|
|
CERN
55
DELISTED
Cerner Corp
CERN
| $214K | 0.02% |
+3,563
| New | +$233K |
2015 Q3
0 quarters
|
|
56
Standard BioTools
LAB
$248M
| $199K | 0.02% |
24,583
-323,654
| -93% | -$5.09M |
2014 Q2
5 quarters
|
|
|
NXTM
57
DELISTED
NxStage Medical Inc.
NXTM
| $186K | 0.01% |
+11,800
| New | +$189K |
2015 Q3
0 quarters
|
|
|
58
AbbVie
ABBV
$501B
| – | – |
-510,010
| Closed | -$34.3M | – |
|
|
59
Bausch Health
BHC
$2.2B
| – | – |
-384,506
| Closed | -$85.4M | – |
|
60
Biogen
BIIB
$34.4B
| – | – |
-79,118
| Closed | -$32M | – |
|
61
Cigna
CI
$76.5B
| – | – |
-198,700
| Closed | -$32.2M | – |
|
62
DaVita
DVA
$11.5B
| – | – |
-140,191
| Closed | -$11.1M | – |
|
|
63
HCA Healthcare
HCA
$102B
| – | – |
-390,000
| Closed | -$35.4M | – |
|
64
iShares US Healthcare Providers ETF
IHF
$1.41B
| – | – |
-42,995
| Closed | -$1.23M | – |
|
65
Ultragenyx Pharmaceutical
RARE
$1.47B
| – | – |
-67,425
| Closed | -$6.9M | – |
|
66
Universal Health Services
UHS
$11B
| – | – |
-175,965
| Closed | -$25M | – |
|
|
BLCM
67
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
| – | – |
-23,812
| Closed | -$5.07M | – |
|
|
SIOX
68
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| – | – |
-18,750
| Closed | -$3.06M | – |
|
69
DELISTED
Flexion Therapeutics, Inc.
FLXN
| – | – |
-142,483
| Closed | -$3.12M | – |
|
|
GWPH
70
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| – | – |
-146,027
| Closed | -$17.9M | – |
|
|
AGN
71
DELISTED
Allergan plc
AGN
| – | – |
-136,818
| Closed | -$41.5M | – |
|
72
DELISTED
Civitas Solutions, Inc.
CIVI
| – | – |
-657,693
| Closed | -$14M | – |
|
|
AET
73
DELISTED
Aetna Inc
AET
| – | – |
-264,075
| Closed | -$33.7M | – |
|
|
ALR
74
DELISTED
Alere Inc
ALR
| – | – |
-461,170
| Closed | -$24.3M | – |
|
|
KYTH
75
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
| – | – |
-482,556
| Closed | -$36.3M | – |
|
Similar funds
FCM
MM
WA
ACB
LCS
GAM
MFWP
PMG
Redmile Group's Q3 2015 Portfolio in Review
As of Q3 2015, Redmile Group held 77 positions worth $1.32B, up 8.2% from $1.22B the previous quarter. Its ten largest holdings account for 53% of the portfolio.
Redmile Group deployed $327M of net new capital in Q3 2015, opening 22 new positions and adding to 20 existing holdings. Its largest new stake was MEDIVATION, INC.: 1,752,642 shares worth $74.5M.
By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 87% a quarter earlier, followed by Miscellaneous and Communication Services.
On the sell side, the largest reduction was Jazz Pharmaceuticals, an estimated $25.7M trimmed.
- Redmile Group's largest Q3 2015 buy was MEDIVATION, INC.: 1,752,642 shares worth $74.5M.
- Redmile Group added most to Sage Therapeutics in Q3 2015, an estimated $52.5M increase.
- Redmile Group's biggest Q3 2015 reduction was Jazz Pharmaceuticals, cutting an estimated $25.7M.
- Redmile Group fully exited Bausch Health in Q3 2015, selling an estimated $85.4M.
- Redmile Group's ten largest holdings make up 53% of its $1.32B portfolio in Q3 2015.
- Redmile Group opened 22 new positions and closed 19 in Q3 2015.
- Redmile Group's portfolio value rose 8.2% quarter-over-quarter to $1.32B.
Based on Redmile Group's 13F filing for Q3 2015, filed 17 Nov 2015.